Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.

Autor: García-Muñoz R; Department of Haematology, Complejo Hospitalario San Millán-San Pedro, Logroño, Spain., Quero C; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Pérez-Persona E; Department of Haematology, Hospital de Txagorritxu, Vitoria-Gasteiz, Spain., Domingo-García A; Department of Haematology, Hospital General de Granollers, Granollers, Spain., Pérez-López C; Department of Haematology, Hospital Universitario Clínico San Carlos, Madrid, Spain., Villaescusa-de-la-Rosa T; Department of Haematology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Martínez-Castro AM; Department of Haematology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Arguiñano-Pérez JM; Department of Haematology, Hospital de Navarra, Pamplona, Spain., Parra-Cuadrado JF; Medical Department, Roche Farma S.A., Madrid, Spain., Panizo C; Department of Haematology, Clínica Universidad de Navarra, Pamplona, Spain.

Publikováno v: British journal of haematology [Br J Haematol] 2020 Mar; Vol. 188 (5), pp. 661-673. Date of Electronic Publication: 2019 Oct 01.